Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled "Compositions and methods for enzymatic detachment of bacterial and fungal biofilms" by IP Australia (Australian Patent and Trademark Office). Australia is the third country to issue a patent covering Kane Biotech's DispersinB^® anti-biofilm technology.

This patent claims the gene encoding DispersinB^® enzyme and also the amino acid sequence of the enzyme. In addition, the claims include: (i) a method of producing DispersinB^®, (ii) pharmaceutical compositions comprising DispersinB^® and an antibody or an antibiotic/antimicrobial, (iii) methods of administration, and (iv) applications in medical devices, wound care and oral care. Kane Biotech and many independent researchers around the world have demonstrated the in vitro and in vivo efficacy of the DispersinB^® antibiofilm enzyme in numerous studies.

"We are very pleased that our DispersinB^® patents are beginning to issue around the World and we now have patent protection in the United States, New Zealand and Australia, with pending patents in other countries as well", stated Gord Froehlich, President and CEO of Kane Biotech.